Pure Global AI
NCT05800600Recruiting

Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy

Fox Chase Cancer CenterPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Anemia
Drug/Device/Intervention
Venofer
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Fox Chase Cancer Center
Location
Philadelphia, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Mar 15, 2023
End date
Feb 01, 2026
Enrollment
34 participants
Primary outcome

Mean change from baseline to highest Hgb value

Summary

This is an open-label, single institution study evaluating the efficacy of intravenous iron
 sucrose monotherapy in patients with thoracic, breast, GU and GI malignancies undergoing
 neoadjuvant chemotherapy with the goal of undergoing surgical resection.

ICD-10 classifications
Anaemia, unspecifiedOther anaemiasOther specified anaemiasIron deficiency anaemiaIron deficiency anaemia, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05800600
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05800600 through Pure Global AI's free database. This Phase 2 trial is sponsored by Fox Chase Cancer Center and is currently Recruiting. The study focuses on Anemia. Target enrollment is 34 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.